Is retifanlimab used as a first-line treatment for Merkel Cell Carcinoma?
Retifanlimab is a programmed death receptor-1 (PD-1) blocking antibody used to treat certain types of Merkel cell carcinoma (MCC). While it is an option for advanced cases, the primary treatment for early-stage, non-metastatic Merkel cell carcinoma is typically surgical removal.
What the research says
Retifanlimab is specifically indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma 4. Other immune checkpoint inhibitors, such as avelumab and pembrolizumab, are also recognized as first-line treatment options for patients with locally advanced or metastatic Merkel cell carcinoma 6.
For patients with non-metastatic Merkel cell carcinoma, the standard first-line treatment is complete resection (surgical removal) of the tumor 5. In specific cases where surgery or radiation is not possible due to the location of the tumor or the patient's underlying health conditions, immune checkpoint inhibitors like retifanlimab or avelumab may be used 5.
What to ask your doctor
- Is my Merkel cell carcinoma metastatic or locally advanced, and how does that affect my treatment options?
- Is retifanlimab an appropriate first-line treatment for my specific stage of disease?
- What are the risks and benefits of using an immune checkpoint inhibitor like retifanlimab compared to other treatments?
- What is the standard of care for my specific type and location of Merkel cell carcinoma?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.